Background: Altered cerebrospinal fluid (CSF) levels of lactate have been described in neurodegenerative diseases and related to mitochondrial dysfunction and neuronal degeneration. We investigated the relationship between CSF lactate levels, disease severity, and biomarkers associated with neuroaxonal damage in patients with multiple sclerosis (MS).Methods: One-hundred eighteen subjects with relapsing-remitting multiple sclerosis (RRMS) were included, along with one-hundred fifty seven matched controls. CSF levels of lactate, tau protein, and neurofilament light were detected at the time of diagnosis. Patients were followed-up for a mean of 5 years. Progression index (PI), multiple sclerosis severity scale (MSSS), and Bayesian risk estimate for multiple sclerosis (BREMS) were assessed as clinical measures of disease severity and progression. Differences between groups and correlation between CSF lactate, disease severity and CSF biomarkers of neuronal damage were explored.Results: CSF lactate was higher in RRMS patients compared to controls. A negative correlation was found between lactate levels and disease duration. Patients with higher CSF lactate concentration had significantly higher PI, MSSS, and BREMS scores at long-term follow-up. Furthermore, CSF lactate correlated positively and significantly with CSF levels of both tau protein and neurofilament light protein.Conclusions: Measurement of CSF lactate may be helpful, in conjunction with other biomarkers of tissue damage, as an early predictor of disease severity in RRMS patients. A better understanding of the alterations of mitochondrial metabolic pathways associated to RRMS severity may pave the way to new therapeutic targets to contrast axonal damage and disease severity.

Albanese, M., Zagaglia, S., Landi, D., Boffa, L., Nicoletti, C.g., Marciani, M.g., et al. (2016). Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. JOURNAL OF NEUROINFLAMMATION, 13(1), 36 [10.1186/s12974-016-0502-1].

Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression

Albanese, Maria;Landi, Doriana;Marciani, Maria Grazia;Marfia, Girolama A;Buttari, Fabio;Centonze, Diego
2016-02-10

Abstract

Background: Altered cerebrospinal fluid (CSF) levels of lactate have been described in neurodegenerative diseases and related to mitochondrial dysfunction and neuronal degeneration. We investigated the relationship between CSF lactate levels, disease severity, and biomarkers associated with neuroaxonal damage in patients with multiple sclerosis (MS).Methods: One-hundred eighteen subjects with relapsing-remitting multiple sclerosis (RRMS) were included, along with one-hundred fifty seven matched controls. CSF levels of lactate, tau protein, and neurofilament light were detected at the time of diagnosis. Patients were followed-up for a mean of 5 years. Progression index (PI), multiple sclerosis severity scale (MSSS), and Bayesian risk estimate for multiple sclerosis (BREMS) were assessed as clinical measures of disease severity and progression. Differences between groups and correlation between CSF lactate, disease severity and CSF biomarkers of neuronal damage were explored.Results: CSF lactate was higher in RRMS patients compared to controls. A negative correlation was found between lactate levels and disease duration. Patients with higher CSF lactate concentration had significantly higher PI, MSSS, and BREMS scores at long-term follow-up. Furthermore, CSF lactate correlated positively and significantly with CSF levels of both tau protein and neurofilament light protein.Conclusions: Measurement of CSF lactate may be helpful, in conjunction with other biomarkers of tissue damage, as an early predictor of disease severity in RRMS patients. A better understanding of the alterations of mitochondrial metabolic pathways associated to RRMS severity may pave the way to new therapeutic targets to contrast axonal damage and disease severity.
10-feb-2016
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26 - NEUROLOGIA
English
Con Impact Factor ISI
CSF
EDSS
Inflammation
Mitochondrial damage
MS
Neurofilaments
Neurodegeneration
Tau protein
Adult
Case-Control Studies
Disability Evaluation
Disease Progression
Female
Humans
Lactic Acid
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis
Neurofilament Proteins
Neurologic Examination
Statistics, Nonparametric
Young Adult
tau Proteins
Albanese, M., Zagaglia, S., Landi, D., Boffa, L., Nicoletti, C.g., Marciani, M.g., et al. (2016). Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. JOURNAL OF NEUROINFLAMMATION, 13(1), 36 [10.1186/s12974-016-0502-1].
Albanese, M; Zagaglia, S; Landi, D; Boffa, L; Nicoletti, Cg; Marciani, Mg; Mandolesi, G; Marfia, Ga; Buttari, F; Mori, F; Centonze, D
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
9_Albanese, 2017.pdf

solo utenti autorizzati

Licenza: Non specificato
Dimensione 792.46 kB
Formato Adobe PDF
792.46 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/306401
Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 59
  • ???jsp.display-item.citation.isi??? 58
social impact